GlaxoSmithKline PLC — Director's Dealing 2017

Feb 21, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4792X

GlaxoSmithKline PLC

21 February 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sir Andrew Witty
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	67,867 (Deferred)
	£0.0000	22,621 (Matching)
d)	Aggregated information
Aggregated volume Price	90,448 £0.0000
e)	Date of the transaction	2017-02-20
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sir Andrew Witty
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£16.3353	31,898 (Deferred)
	£16.3353	10,633 (Matching)
d)	Aggregated information
Aggregated volume Price	42,531 £16.3353
e)	Date of the transaction	2017-02-20
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	CEO Designate
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	14,860 (Deferred)
	£0.0000	4,954 (Matching)
d)	Aggregated information
Aggregated volume Price	19,814 £0.0000
e)	Date of the transaction	2017-02-21
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	CEO Designate
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£16.3500	6,986 (Deferred)
	£16.3500	2,330 (Matching)
d)	Aggregated information
Aggregated volume Price	9,316 £16.3500
e)	Date of the transaction	2017-02-21
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	12,115 (Deferred)
	£0.0000	4,039 (Matching)
d)	Aggregated information
Aggregated volume Price	16,154 £0.0000
e)	Date of the transaction	2017-02-20
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£16.3425	5,809 (Deferred)
	£16.3450	1,937 (Matching)
d)	Aggregated information
Aggregated volume Price	7,746 £16.3431
e)	Date of the transaction	2017-02-20
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	7,517 (Deferred)
	£0.0000	2,506 (Matching)
d)	Aggregated information
Aggregated volume Price	10,023 £0.0000
e)	Date of the transaction	2017-02-20
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£16.3700	3,604 (Deferred)
	£16.3550	1,202 (Matching)
d)	Aggregated information
Aggregated volume Price	4,806 £16.3662
e)	Date of the transaction	2017-02-20
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P C Thomson
b)	Position/status	SVP, Communications & Government Affairs
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.0000	4,528 (Deferred)
	£0.0000	1,509 (Matching)
d)	Aggregated information
Aggregated volume Price	6,037 £0.0000
e)	Date of the transaction	2017-02-20
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P C Thomson
b)	Position/status	SVP, Communications & Government Affairs
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 20 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£16.3450	2,171 (Deferred)
	£16.3500	724 (Matching)
d)	Aggregated information
Aggregated volume Price	2,895 £16.3462
e)	Date of the transaction	2017-02-20
f)	Place of the transaction	London Stock Exchange (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDFLFLDLFFBBL